China Biggest Manufacturer factory sales Iron Dextran CAS 9004-66-4 CAS NO.9004-66-4

                                PRODUCT DETAILS                           

Iron-dextran Basic information Product Name: Iron-dextran Synonyms: fe-dextran;fenate;ferdex100;ferricdextran;ferridextran;ferrodextran;ferroglucin;ferroglukin75 CAS: 9004-66-4 MF: FeH2O4S MW: 153.92348 EINECS: 202-785-7 Product Categories: API;API's Mol File: 9004-66-4.mol   Iron-dextran Chemical Properties storage temp.  Room Temperature solubility  Water (Slightly) form  solution color  Very Dark Red to Black IARC 2B (Vol. 2, Sup 7) 1987 EPA Substance Registry System Iron dextran (9004-66-4)   Safety Information Hazard Codes  Xn,T Risk Statements  40-42/43-43-45 Safety Statements  23-26-36/37/39-45-36-36/37-53 WGK Germany  - RTECS  NI2200000 Hazardous Substances Data 9004-66-4(Hazardous Substances Data) Toxicity LD50 i.v. in mice: 2240 mg Fe/kg (Beliles) MSDS Information Provider Language Ferric hydroxide dextran complex English SigmaAldrich English   Iron-dextran Usage And Synthesis Description Iron dextran is a dark brown, slightly viscous liquid complex of ferric hydroxide and dextran for intravenous or intramuscular use. Iron Dextran is used for the treatment of patients with documented iron deficiency in which oral administration is unsatisfactory or impossible. It is supplied as a parenteral preparation and is used as a hematinic. (Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p1292) Iron-Dextran is for the parenteral treatment of iron-deficiency anemia in humans and baby pigs. Can be used as a reagent. Chemical Properties Light to dark brown powder. Colloidal suspension of an iron-dextran complex in water. pH 5.2-6.5. History The therapeutic value of colloidal iron preparations was first reported in the 1950's by London and Twigg. Numerous attempts have been made to improve these iron preparations Thus dextran ([h] 0.05) is first heated with alkali, and is then neutralized in the presence of ferric chloride solution. Studies on this product have revealed that each particle consists of a central iron core, approximately 3nm diameter, surrounded by a dextran sheath of approximately 13nm diameter. The complex is visualized as a particle formed by a protective sheath of dextran attached by terminal metasaccharinic acid units to a b-FeOOH core. A solution of this complex containing 5% iron and 20% dextran (Imferon ™ ) is suitable for intramuscular and intravenous injection for treating iron deficiency anemia. The product is currently used widely for treating anemia in new-born piglets. The use of these preparations has been re-examined in humans and a dramatic rise in hemoglobin was reported following intravenous infusion. The solution is best administered together with glucose solutions. Uses Hematinic. Uses Iron-Dextran (ferric hydroxide dextran complex) may be used as an intravenous iron delivery preparation. Iron-Dextran may be used to induce iron-overload to study its effects and preventative measures. Brand name Dexferrum (Luitpold); Infed (Wat son); Proferdex (New River). Reactivity Profile Iron-dextran is unstable at a pH of 5 and decomposes at 149-158° F. Iron-dextran may be sensitive to prolonged exposure to air. Health Hazard SYMPTOMS: The symptoms associated with exposure to Iron-dextran are headaches, vomiting, and dizziness. Fire Hazard Iron-dextran is combustible. Clinical Use Prophylaxis of iron deficiency anaemia (when oral treatment is ineffective or contraindicated) Treatment of iron deficiency during ESA therapy especially if serum ferritin is very low (<50 nanograms/mL) Drug interactions Potentially hazardous interactions with other drugs Dimercaprol: avoid concomitant use. Oral iron: reduced absorption of oral iron Carcinogenicity Iron dextran complex is reasonably anticipated to be a human carcinogen based on sufficient evidence of carcinogenicity from studies in experimental animals. Metabolism After intravenous infusion, iron dextran is taken up by the cells of the reticuloendothelial cells, particularly in the liver and spleen. The reticuloendothelial cells gradually separate iron from the iron-dextran complex. Most absorbed iron is bound to transferrin and transported to the bone marrow where it is incorporated into haemoglobin; the remainder is contained within the storage forms, ferritin or haemosiderin, or as myoglobin, with smaller amounts occurring in haem-containing enzymes or in plasma bound to transferrin. Only very small amounts of iron are excreted as the majority released after the destruction of the haemoglobin molecule is re-used.   Iron-dextran Preparation Products And Raw materials Preparation Products Dextran

                                      Group profiles

Leader Biochemical Group is a large leader incorporated industry manufacturers and suppliers of advanced refined raw materials From the year of 1996 when our factory was put into production to year of 2020, our group has successively invested in more than 52 factories with shares and subordinates.We focus on manufacture Pharm & chemicals, functional active ingredients, nutritional Ingredients, health care products, cosmetics, pharmaceutical and refined feed, oil, natural plant ingredients industries to provide top quality of GMP standards products.All the invested factories' product lines cover API and intermediates, vitamins, amino acids, plant extracts, daily chemical products, cosmetics raw materials, nutrition and health care products, food additives, feed additives, essential oil products, fine chemical products and agricultural chemical raw materials And flavors and fragrances. Especially in the field of vitamins, amino acids, pharmaceutical raw materials and cosmetic raw materials, we have more than 20 years of production and sales experience. All products meet the requirements of high international export standards and have been recognized by customers all over the world. Our manufacture basement & R&D center located in National Aerospace Economic & Technical Development Zone Xi`an Shaanxi China. Now not only relying on self-cultivation and development as well as maintains good cooperative relations with many famous research institutes and universities in China. Now, we have closely cooperation with Shanghai Institute of Organic Chemistry of Chinese Academy of Science, Beijing Institute of Material Medical of Chinese Academy of Medical Science, China Pharmaceutical University, Zhejiang University. Closely cooperation with them not only integrating Science and technology resources, but also increasing the R&D speed and improving our R&D power. Offering Powerful Tech supporting Platform for group development. Keep serve the manufacture and the market as the R&D central task, focus on the technical research.  Now there are 3 technology R & D platforms including biological extract, microorganism fermentation and chemical synthesis, and can independently research and develop kinds of difficult APIs and pharmaceutical intermediates. With the strong support of China State Institute of Pharmaceutical Industry (hereinafter short for CSIPI), earlier known as Shanghai Institute of Pharmaceutical Industry (SIPI), we have unique advantages in the R & D and industrialization of high-grade, precision and advanced products.  Now our Group technical force is abundant, existing staff more that 1000 people, senior professional and technical staff accounted for more than 50% of the total number of employees, including 15 PhD research and development personnel, 5 master′ S degree in technical and management personnel 9 people. We have advanced equipment like fermentation equipment and technology also extraction, isolation, purification, synthesis with rich production experience and strict quality control system, According to the GMP required, quickly transforming the R&D results to industrial production in time, it is our advantages and our products are exported to North and South America, Europe, Middle East, Africa, and other five continents and scale the forefront in the nation, won good international reputation.  We believe only good quality can bring good cooperation, quality is our key spirit during our production, we are warmly welcome clients and partner from all over the world contact us for everlasting cooperation, Leader will be your strong, sincere and reliable partner in China.

Our Factories production lines

                                                   Our Factories R&D ability

                        Our Factories warehouse 

                                                       Product information

Iron-dextran Basic information Product Name: Iron-dextran Synonyms: fe-dextran;fenate;ferdex100;ferricdextran;ferridextran;ferrodextran;ferroglucin;ferroglukin75 CAS: 9004-66-4 MF: FeH2O4S MW: 153.92348 EINECS: 202-785-7 Product Categories: API;API's Mol File: 9004-66-4.mol   Iron-dextran Chemical Properties storage temp.  Room Temperature solubility  Water (Slightly) form  solution color  Very Dark Red to Black IARC 2B (Vol. 2, Sup 7) 1987 EPA Substance Registry System Iron dextran (9004-66-4)   Safety Information Hazard Codes  Xn,T Risk Statements  40-42/43-43-45 Safety Statements  23-26-36/37/39-45-36-36/37-53 WGK Germany  - RTECS  NI2200000 Hazardous Substances Data 9004-66-4(Hazardous Substances Data) Toxicity LD50 i.v. in mice: 2240 mg Fe/kg (Beliles) MSDS Information Provider Language Ferric hydroxide dextran complex English SigmaAldrich English   Iron-dextran Usage And Synthesis Description Iron dextran is a dark brown, slightly viscous liquid complex of ferric hydroxide and dextran for intravenous or intramuscular use. Iron Dextran is used for the treatment of patients with documented iron deficiency in which oral administration is unsatisfactory or impossible. It is supplied as a parenteral preparation and is used as a hematinic. (Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p1292) Iron-Dextran is for the parenteral treatment of iron-deficiency anemia in humans and baby pigs. Can be used as a reagent. Chemical Properties Light to dark brown powder. Colloidal suspension of an iron-dextran complex in water. pH 5.2-6.5. History The therapeutic value of colloidal iron preparations was first reported in the 1950's by London and Twigg. Numerous attempts have been made to improve these iron preparations Thus dextran ([h] 0.05) is first heated with alkali, and is then neutralized in the presence of ferric chloride solution. Studies on this product have revealed that each particle consists of a central iron core, approximately 3nm diameter, surrounded by a dextran sheath of approximately 13nm diameter. The complex is visualized as a particle formed by a protective sheath of dextran attached by terminal metasaccharinic acid units to a b-FeOOH core. A solution of this complex containing 5% iron and 20% dextran (Imferon ™ ) is suitable for intramuscular and intravenous injection for treating iron deficiency anemia. The product is currently used widely for treating anemia in new-born piglets. The use of these preparations has been re-examined in humans and a dramatic rise in hemoglobin was reported following intravenous infusion. The solution is best administered together with glucose solutions. Uses Hematinic. Uses Iron-Dextran (ferric hydroxide dextran complex) may be used as an intravenous iron delivery preparation. Iron-Dextran may be used to induce iron-overload to study its effects and preventative measures. Brand name Dexferrum (Luitpold); Infed (Wat son); Proferdex (New River). Reactivity Profile Iron-dextran is unstable at a pH of 5 and decomposes at 149-158° F. Iron-dextran may be sensitive to prolonged exposure to air. Health Hazard SYMPTOMS: The symptoms associated with exposure to Iron-dextran are headaches, vomiting, and dizziness. Fire Hazard Iron-dextran is combustible. Clinical Use Prophylaxis of iron deficiency anaemia (when oral treatment is ineffective or contraindicated) Treatment of iron deficiency during ESA therapy especially if serum ferritin is very low (<50 nanograms/mL) Drug interactions Potentially hazardous interactions with other drugs Dimercaprol: avoid concomitant use. Oral iron: reduced absorption of oral iron Carcinogenicity Iron dextran complex is reasonably anticipated to be a human carcinogen based on sufficient evidence of carcinogenicity from studies in experimental animals. Metabolism After intravenous infusion, iron dextran is taken up by the cells of the reticuloendothelial cells, particularly in the liver and spleen. The reticuloendothelial cells gradually separate iron from the iron-dextran complex. Most absorbed iron is bound to transferrin and transported to the bone marrow where it is incorporated into haemoglobin; the remainder is contained within the storage forms, ferritin or haemosiderin, or as myoglobin, with smaller amounts occurring in haem-containing enzymes or in plasma bound to transferrin. Only very small amounts of iron are excreted as the majority released after the destruction of the haemoglobin molecule is re-used.   Iron-dextran Preparation Products And Raw materials Preparation Products Dextran